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Purpose of the study
The aim of the Rainbow Cohort is to assess the tolerability
and efficacy of initiating treatment with, or switching
treatment to the saquinavir (SQV) 500 mg film-coated
tablet formulation. We present the final 48-week sub-
group analysis of PI-experienced, but SQV-naïve patients.
Methods
Multicenter, prospective, open label, observational cohort
study. Tolerability assessment included changes in lipids
– stratified according to baseline (BL) levels – from BL to
week 48. Efficacy assessment included changes in CD4
count and viral load (VL). Changes to baseline were tested
for significance with Wilcoxon signed rank test.
Summary of results
Median BL characteristics from evaluable patients (n =
426): 84% male; age 43 years; time since first HIV diagno-
sis 9 years (IQR 4; 14); VL 599 cp/mL (IQR <50; 31,291);
VL<50 cp/mL 33.6%; CD4 count 320 cells/mm3 (IQR
177; 506). Week 48 results: Median CD4 increase was +61
cells/mm3 (IQR -9; 170; p < 0.01); 60.3% of patients
achieved a VL <50 cp/mL (ITT, LOCF analysis). SQV treat-
ment was stopped in 22% of the patients (6% due to side-
effects, 4% due to virological failure). Stratified according
to BL triglyceride levels, median changes (ITT, LOCF anal-
ysis) were +14 mg/dL (IQR -8; 57) for patients with <200
mg/dL (p < 0.01; n = 196); -50 mg/dL (IQR -139; 0) for
patients with 200–750 mg/dL (p < 0.01; n = 136) and -
656 mg/dL (IQR -1024; 0) for patients with >750 mg/dL
(p < 0.01; n = 15), respectively. Stratified according to BL
total cholesterol levels, median changes (ITT, LOCF anal-
ysis) were +16 mg/dL (IQR -3; 43) for patients with <200
mg/dL (p < 0.01; n = 206); -3 mg/dL (IQR -25; 25) for
patients with 200–300 mg/dL (p = 0.4; n = 121) and -47
mg/dL (IQR -87; -4) for patients with >300 mg/dL (p <
0.01; n = 11), respectively. No significant changes of ALT,
AST, γ-GT, or bilirubin were observed. See Figure 1.
Conclusion
These data confirm that SQV/r is effective and well toler-
ated in PI-experienced, SQV-naïve patients in a real-life
clinical setting. Most relevant improvements in triglycer-
ides and total cholesterol levels were observed in patients
with baseline grade III–IV elevation.
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Median changes in triglycerides (LOCF) from baseline to week 48 – stratified according to baseline level – after start of an  SQV/r containing antiretroviral therapy in PI-pretreated, but SQV-naïve patients Figure 1
Median changes in triglycerides (LOCF) from baseline to week 48 – stratified according to baseline level – after start of an 
SQV/r containing antiretroviral therapy in PI-pretreated, but SQV-naïve patients.